Myelin oligodendrocyte glycoprotein antibody-associated disease
MONDO:1040024A demyelinating disease of the central nervous system characterized by the presence of a demyelinating event (optic neuritis, myelitis, acute/multiphasic encephalomyelitis, cerebral or polyfocal deficits, brainstem or cerebellar deficits, and/or cerebral cortical encephalitis), a positive myelin oligodendrocyte glycorotein-IgG test, and exclusion of an alternative diagnosis like MS.
21 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Promising drug aims to stop Flare-Ups in rare brain disease
Disease control OngoingThis study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to stop relapses in rare brain disease
Disease control OngoingThis phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
CAR-T therapy targets autoimmune diseases, but trial never started
Disease control TerminatedThis study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was wi…
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for MOGAD patients: drug aims to stop relapses
Disease control OngoingThis study tests whether the drug tocilizumab can safely prevent or delay relapses in people with MOGAD, a rare autoimmune disease that attacks the nervous system. About 102 participants aged 12 and older who have had at least one relapse in the past year will receive either toci…
Phase: PHASE2, PHASE3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC